Stepping Towards Predictive Biomanufacturing

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced an agreement to apply Insilico's predictive Digital Twins for the early selection of high-performing cell lines to enable accelerated development of highly economic and robust production processes. The partnership will develop an automated workflow for predictive clone selection by combining the expertise in cell line development and predictive modelling of cell cultures.

Insilico's Digital Twins are digital models of cells in their bioprocess which allow for virtual experimentation to replace time-consuming wet lab experiments. Clone-specific models enable the selection of the best producer cells in high-throughput scale-down systems by predicting an individual clone's performance and robustness in large scale and its improvement potential under optimised media and feeding conditions

"The use of Insilico’s predictive Digital Twins for clone selection is a great example of combining state-of-the-art modelling and experimental expertise. Looking back at several years of successful collaboration, we see a great potential to further shorten our development timelines and thus bring high-quality biopharmaceutical products to patients in the shortest possible time." said Kevin D. Smith, PhD, Head of Cell Line Development of Janssen Research & Development, LLC.

"Automated workflows for clone selection not only result in more robust and efficient processes, but allow Janssen to select the best production clone very early. This saves a significant amount of wet lab experiments and thus shortens development timelines. We are very excited to collaboratively develop a faster and more economic clone selection workflow for Janssen." said Klaus Mauch, CEO of Insilico Biotechnology AG.

The collaboration will run for three years and will be based at Insilico's Stuttgart site in germanyGermany and at Janssen's Spring House location in the USA.